GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)
Status:
RECRUITING
Trial end date:
2027-09-10
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label and early exploratory clinical study, with the purpose to study the safety, tolerability and initial clinical efficacy of GC012F Injection in the treatment of refractory GMG and to evaluate the PK, PD characteristics and immunogenicity in subjects with refractory GMG infused with GC012F Injection.